The authors also showed that adding the poly-ADP-ribose polymerase (PARP) inhibitor olaparib to PI3K inhibitors markedly attenuated tumor activity in triple negative breast cancer with wild-type BRCA1. Here, PIK3CB is linked to triple-negative breast carcinoma.